<DOC>
	<DOCNO>NCT00454337</DOCNO>
	<brief_summary>Switching enfuvirtide raltegravir treatment HIV-infected patient sustain viral suppression combination therapy include enfuvirtide ( : enfuvirtide-based combination therapy )</brief_summary>
	<brief_title>Efficacy Tolerance Switch From Enfuvirtine Raltegravir Antiretroviral Therapy Regimen HIV Patients With Undetectable Viral Load</brief_title>
	<detailed_description>In patient fail three main class antiretroviral agent ( NRTI , NNRTI PI ) control viral replication plasma ultimately achieve enfuvirtide , aim sustain virological success long possible thus enable satisfactory immune reconstitution , avoid accumulation viral mutation confer resistance drug protect patient risk opportunistic disease death . Indeed , enfuvirtide lead compound new class antiretroviral drug inhibit fusion HIV-1 virus target cell . Its vivo efficacy demonstrate pivotal study TORO 1 2 . Despite efficacy , maintain long-term treatment enfuvirtide nonetheless difficult patient constraint related twice-daily subcutaneous parenteral injection . Furthermore , subcutaneous injection associate inflammatory reaction injection site 98 per cent patient , without reduction frequency severity time . It thus critical patient well control enfuvirtide able simplify treatment replace enfuvirtide another active compound take mouth , would enable maintenance virological response acceptable safety patient usually fail three main class antiretroviral drug . A new antiviral compound , viral integrase inhibitor call raltegravir , could propose instead enfuvirtide .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Chronic HIV1 infection Treatment welltolerated combination antiretroviral drug unchanged least 3 month , include enfuvirtide Absence uncontrolled opportunistic disease No restriction CD4 lymphocyte level Plasma HIV1 RNA 400 copy per ml least 3 month ( least two consecutive test 400 copy per ml prior inclusion study , include W 4 ) For woman childbearing age , use mechanical contraception sexual intercourse negative pregnancy test ( plasma ÃŸ HCG ) W 4 HIV2 infection Plasma HIV1 RNA level 400 copies/ml one occasion 3 month prior screen ( preinclusion visit W 4 ) Poor compliance antiretroviral therapy current W 4 Current treatment investigational drug ( except cohort ATU ) Patient previously treat integrase inhibitor context clinical study Woman pregnant likely become , breastfeed refuse use contraception Multiple drug therapy ongoing necessary foreseeable future Kaposi 's disease lymphoma Treatment interferon ongoing necessary foreseeable future chronic hepatitis B C Acute hepatitis whatever case , decompensated cirrhosis Current treatment interferon , interleukin antiHIV vaccine Any condition ( include , limited , consumption alcohol drug ) might , investigator 's opinion , compromise safety treatment and/or patient compliance protocol Significant biological abnormality ( hemoglobin 8g per dl , polynuclear neutrophils 750 per mm3 , platelets 50,000 per mm3 , serum creatinine 3 time level deem normal laboratory ( N ) , ASAT ALAT 5N , serum lipase 2N ) total bilirubin 2N ( except patient receive atazanavir indinavir ) Concomitant treatment include one compound interact UGT1A1 antiinfective agent : rifampicin/rifampin psychotropic/antiepileptic drug : phenytoin , phenobarbital .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>enfuvirtide</keyword>
	<keyword>raltegravir</keyword>
	<keyword>treatment experience</keyword>
</DOC>